SA519410253B1 - Erk1/2 مشتق 6- بيريميدين أيزوإندول كمثبط - Google Patents
Erk1/2 مشتق 6- بيريميدين أيزوإندول كمثبطInfo
- Publication number
- SA519410253B1 SA519410253B1 SA519410253A SA519410253A SA519410253B1 SA 519410253 B1 SA519410253 B1 SA 519410253B1 SA 519410253 A SA519410253 A SA 519410253A SA 519410253 A SA519410253 A SA 519410253A SA 519410253 B1 SA519410253 B1 SA 519410253B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- compound
- pyrimidin
- erk1
- inhibitor
- isoindole derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706327.2A GB201706327D0 (en) | 2017-04-20 | 2017-04-20 | A pharmaceutical compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA519410253B1 true SA519410253B1 (ar) | 2023-07-12 |
Family
ID=58795788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA519410253A SA519410253B1 (ar) | 2017-04-20 | 2019-10-03 | Erk1/2 مشتق 6- بيريميدين أيزوإندول كمثبط |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11142518B2 (https=) |
| EP (1) | EP3612524B1 (https=) |
| JP (1) | JP7113846B2 (https=) |
| KR (1) | KR102652193B1 (https=) |
| CN (1) | CN110831939B (https=) |
| AU (1) | AU2018255935B2 (https=) |
| CA (1) | CA3059674A1 (https=) |
| DK (1) | DK3612524T3 (https=) |
| ES (1) | ES2994283T3 (https=) |
| FI (1) | FI3612524T3 (https=) |
| GB (1) | GB201706327D0 (https=) |
| IL (1) | IL269803B (https=) |
| MA (1) | MA52123A (https=) |
| MX (1) | MX2019012471A (https=) |
| MY (1) | MY203722A (https=) |
| PH (1) | PH12019502154A1 (https=) |
| SA (1) | SA519410253B1 (https=) |
| SG (1) | SG11201909189QA (https=) |
| TW (1) | TWI813566B (https=) |
| WO (1) | WO2018193410A1 (https=) |
| ZA (1) | ZA201907484B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3365334B1 (en) | 2015-10-21 | 2024-07-17 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| NZ766835A (en) | 2018-03-02 | 2023-09-29 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
| JP7174143B2 (ja) | 2018-07-24 | 2022-11-17 | 大鵬薬品工業株式会社 | Ｓｈｐ２活性を阻害するヘテロ二環性化合物 |
| CN109608444B (zh) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | 含异吲哚啉酮的erk抑制剂及其制备方法与用途 |
| GB201911928D0 (en) | 2019-08-20 | 2019-10-02 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
| EP4093406A4 (en) * | 2020-01-24 | 2024-02-28 | Taiho Pharmaceutical Co., Ltd. | IMPROVEMENT OF THE ANTI-TUMORAL ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NEW ANTI-CANCER DRUGS AGAINST CANCER |
| WO2021218912A1 (zh) * | 2020-04-30 | 2021-11-04 | 南京明德新药研发有限公司 | 含苯基并内磺酰胺的化合物 |
| CN113967198A (zh) * | 2020-07-24 | 2022-01-25 | 鲁南制药集团股份有限公司 | 一种甾体cyp17抑制剂胶囊及其制备方法 |
| CA3190001A1 (en) * | 2020-08-21 | 2022-02-24 | Shanghai Ringene Biopharma Co., Ltd. | Aromatic ring-lactam compound, preparation method therefor and use thereof |
| US20240287051A1 (en) * | 2021-06-11 | 2024-08-29 | Otsuka Pharmaceutical Co., Ltd. | Process for preparing an erk inhibitor |
| WO2023059885A1 (en) * | 2021-10-08 | 2023-04-13 | Slayback Pharma Llc, | Stable pharmaceutical compositions of cyclophosphamide |
| US20240415835A1 (en) * | 2021-10-26 | 2024-12-19 | Otsuka Pharmaceutical Co., Ltd. | Compositions comprising an erk inhibitor |
| CN114085213B (zh) * | 2022-01-20 | 2022-03-25 | 苏州国匡医药科技有限公司 | 一种arv-471的制备方法 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5958934A (en) | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
| CA2333927A1 (en) | 1998-04-01 | 1999-10-07 | Dupont Pharmaceuticals Company | Pyrimidines and triazines as integrin antagonists |
| JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ７に対するピリミジン阻害剤 |
| CA2524221A1 (en) | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Substituted heteroaryls as inhibitors of protein tyrosine phosphatases |
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| EP1663204B1 (en) | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | C-kit modulators and methods of use |
| LT3305776T (lt) | 2004-05-14 | 2020-01-10 | Vertex Pharmaceuticals Incorporated | Pirolo junginiai kaip erk baltymo kinazės inhibitoriai, ir farmacinės kompozicijos su šiais junginiais |
| US20060235036A1 (en) | 2005-04-15 | 2006-10-19 | Doherty Elizabeth M | Vanilloid receptor ligands and their use in treatments |
| HRP20110892T1 (hr) | 2005-12-13 | 2011-12-31 | Schering Corporation | Policiklični derivati indazola koji su inhibitori erk |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| JP2009542604A (ja) | 2006-07-06 | 2009-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ４−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用 |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| WO2009039635A1 (en) | 2007-09-24 | 2009-04-02 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| US20100267712A1 (en) | 2007-09-27 | 2010-10-21 | The United States of America, as represented by the Secretary, Department of Health and | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| KR20100110367A (ko) | 2008-01-24 | 2010-10-12 | 메르크 파텐트 게엠베하 | 당뇨병 치료를 위한 베타-아미노산 유도체들 |
| TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| JP5487214B2 (ja) | 2008-12-19 | 2014-05-07 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物 |
| US8716326B2 (en) | 2009-05-15 | 2014-05-06 | Korea Research Institute Of Chemical Technology | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same |
| WO2010151747A1 (en) | 2009-06-26 | 2010-12-29 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimine compounds and methods of making and using same |
| WO2011008931A2 (en) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| AU2010341573B2 (en) | 2009-12-22 | 2016-10-13 | Vertex Pharmaceuticals Incorporated | Isoindolinone inhibitors of phosphatidylinositol 3-kinase |
| AU2010336027A1 (en) | 2009-12-23 | 2012-07-19 | Auckland Uniservices Limited | Compounds, preparations and uses thereof |
| BR112012016178A2 (pt) | 2009-12-31 | 2015-10-06 | Piramal Healthcare Ltd | inibidores de diacilglicerol aciltransferase |
| US9200008B2 (en) | 2010-07-02 | 2015-12-01 | Aska Pharmaceutical Co., Ltd. | Heterocyclic compound and p27Kip1 degradation inhibitor |
| BR112013002112B1 (pt) | 2010-07-29 | 2021-04-06 | Rigel Pharmaceuticals, Inc. | Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| HUE053994T2 (hu) | 2012-03-01 | 2021-08-30 | Array Biopharma Inc | Szerin/treonin kináz inhibitorok |
| CN104583195B (zh) | 2012-09-12 | 2018-08-17 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物 |
| US20150272939A1 (en) | 2012-10-02 | 2015-10-01 | Yale University | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase |
| EP2914296B2 (en) | 2012-11-01 | 2021-09-29 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| AU2014214846A1 (en) | 2013-02-08 | 2015-07-23 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
| WO2014130856A2 (en) | 2013-02-21 | 2014-08-28 | Wayne Rothbaum | Treatment of skeletal-related disorders |
| AR093580A1 (es) | 2013-08-30 | 2015-06-10 | Ptc Therapeutics Inc | Inhibidores bmi-1 de pirimidina sustituidos |
| WO2015048547A2 (en) | 2013-09-26 | 2015-04-02 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| AU2015206652A1 (en) * | 2014-01-14 | 2016-08-04 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| CN106458990B (zh) | 2014-04-04 | 2019-06-07 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| US11311541B2 (en) | 2014-04-09 | 2022-04-26 | Kadmon Corporation, Llc | Treatment of GVHD |
| WO2016025649A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a dot1l inhibitor and related methods |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| WO2016162325A1 (en) | 2015-04-07 | 2016-10-13 | Astrazeneca Ab | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors |
| WO2016205418A1 (en) | 2015-06-15 | 2016-12-22 | Asana Biosciences, Llc | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
| EP3365334B1 (en) * | 2015-10-21 | 2024-07-17 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| RS60155B1 (sr) | 2015-11-09 | 2020-05-29 | Astrazeneca Ab | Derivati dihidroimidazopirazinona korisni za upotrebu u tretmanu raka |
| JP6740452B2 (ja) | 2016-07-26 | 2020-08-12 | 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． | プロテインチロシンキナーゼの活性を阻害するためのアミノピリミジン系化合物 |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
-
2017
- 2017-04-20 GB GBGB1706327.2A patent/GB201706327D0/en not_active Ceased
-
2018
- 2018-04-20 CA CA3059674A patent/CA3059674A1/en active Pending
- 2018-04-20 KR KR1020197033128A patent/KR102652193B1/ko active Active
- 2018-04-20 DK DK18722731.9T patent/DK3612524T3/da active
- 2018-04-20 AU AU2018255935A patent/AU2018255935B2/en active Active
- 2018-04-20 FI FIEP18722731.9T patent/FI3612524T3/fi active
- 2018-04-20 US US16/604,002 patent/US11142518B2/en active Active
- 2018-04-20 WO PCT/IB2018/052745 patent/WO2018193410A1/en not_active Ceased
- 2018-04-20 MX MX2019012471A patent/MX2019012471A/es unknown
- 2018-04-20 CN CN201880024602.7A patent/CN110831939B/zh active Active
- 2018-04-20 IL IL269803A patent/IL269803B/en unknown
- 2018-04-20 EP EP18722731.9A patent/EP3612524B1/en active Active
- 2018-04-20 ES ES18722731T patent/ES2994283T3/es active Active
- 2018-04-20 SG SG11201909189Q patent/SG11201909189QA/en unknown
- 2018-04-20 TW TW107113537A patent/TWI813566B/zh active
- 2018-04-20 MY MYPI2019005656A patent/MY203722A/en unknown
- 2018-04-20 MA MA052123A patent/MA52123A/fr unknown
- 2018-04-20 JP JP2019555918A patent/JP7113846B2/ja active Active
-
2019
- 2019-09-20 PH PH12019502154A patent/PH12019502154A1/en unknown
- 2019-10-03 SA SA519410253A patent/SA519410253B1/ar unknown
- 2019-11-12 ZA ZA2019/07484A patent/ZA201907484B/en unknown
-
2021
- 2021-09-01 US US17/464,166 patent/US12030873B2/en active Active
-
2024
- 2024-05-31 US US18/679,934 patent/US20250002481A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519410253B1 (ar) | Erk1/2 مشتق 6- بيريميدين أيزوإندول كمثبط | |
| MX2022006865A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. | |
| TN2019000136A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| MX2020001832A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre. | |
| MX2019009564A (es) | Sales de clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino ) pirimidin-4-il) benzamida. | |
| PH12015501661B1 (en) | Pyridone amides as modulators of sodium channels | |
| MX2019000536A (es) | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. | |
| MX2021002981A (es) | Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30). | |
| PH12017502067A1 (en) | Insecticidal arylpyrrolidines, method for synthesizing same, and use thereof as agents for controlling animal pests | |
| MY181641A (en) | Amino pyran ring derivative and composition and use thereof | |
| MX379558B (es) | Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3-il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino)-benzamida. | |
| PH12019500569A1 (en) | Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors | |
| MY198008A (en) | Crystal of benzofuran derivative free base and preparation method | |
| MX2021006682A (es) | Inhibidores de descarboxilasa para el tratamiento de la enfermedad de parkinson. | |
| PH12020550125A1 (en) | Crystalline forms of 3-substituted 1,2,4-oxadiazole | |
| EA201691741A1 (ru) | Фармацевтическая композиция | |
| MX2022012998A (es) | Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2 -(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-aci do ciclo-propilpropanoico y su forma cristalina para uso como principio activo farmaceutico. | |
| PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
| PH12019501785B1 (en) | Intranasal composition comprising betahistine | |
| PH12020551736A1 (en) | The crystalline forms of a compound | |
| MX2019009059A (es) | Procesos enzimaticos para la preparacion de acido (±)-2-(difluorometil)-1-(alcoxicarbonil)-ciclopropancarboxilico y +acido (±)-2-(vinil)-1-(alcoxicarbonil)-ciclopropancarboxilico. | |
| MX2019004345A (es) | Formas cristalinas de 4-(2-((1r,2r)-2-hidroxiciclohexilamino) benzotiazol-6-iloxi)-n-metilpicolinamida. | |
| PH12019502792A1 (en) | Tetrahydropyridopyrazine modulators of gpr6 | |
| EA202090346A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ N-((1R,2S,5R)-5-(ТРЕТ-БУТИЛАМИНО)-2-((S)-3-(7-ТРЕТ-БУТИЛПИРАЗОЛО[1,5-a][1,3,5]ТРИАЗИН-4-ИЛАМИНО)-2-ОКСОПИРРОЛИДИН-1-ИЛ)ЦИКЛОГЕКСИЛ)АЦЕТАМИДА | |
| MX2020008082A (es) | Compuestos y composiciones para el tratamiento del dolor. |